Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0736 · 1 trial · 1 indication
Sitting diastolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration. Mean value of the 3 measurements at the 2 timepoints was recorded.
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.
| Arm | Type | Description |
|---|---|---|
| High BMI:MK-0736 2mg→Placebo | EXPERIMENTAL | Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B) |
| High BMI:MK-0736 7mg→Placebo | EXPERIMENTAL | Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B) |
| High BMI:MK-0916 6mg→MK-0916 6mg | EXPERIMENTAL | Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks) |
| High BMI:Placebo→Placebo | PLACEBO_COMPARATOR | Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks) |
| Low BMI:MK-0916 6mg→MK-0916 6mg | EXPERIMENTAL | Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks) |
| Low BMI:Placebo→Placebo | PLACEBO_COMPARATOR | Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks) |
| Name | Type | Description |
|---|---|---|
| MK0736 | DRUG | - |
| MK0916 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Hypertension systolic blood pressure (SBP) \</= 160mm Hg and diastolic blood pressure (DBP): 90-105mm Hg Exclusion Criteria: * Pre-menopausal women * patients currently taking more than two (2) blood pressure lowering medications * Body Mas Index (BMI)\>40 kg/m2 (morbidly ob...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
MK0736 is an investigational small molecule being studied for the treatment of hypertension, or high blood pressure. It was evaluated in a Phase 2 clinical trial in patients with hypertension. MK0736 is not approved for any indication and remains in clinical development.
MK0736 targets HSD11B1, also known as 11 beta hydroxysteroid dehydrogenase type 1. It is an inhibitor of this enzyme. By inhibiting HSD11B1, MK0736 is designed to act on a pathway relevant to blood pressure regulation, which is the basis for its study in hypertension.
MK0736 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck sponsored the clinical trial of MK0736 in hypertension.
MK0736 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
MK0736 has been studied in one completed Phase 2 trial, NCT00274716, titled Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension. The trial enrolled 249 patients, was randomized, double blind, and placebo controlled, and included adults 18 years and older of all sexes.